5-methyltetrahydrofolate Administration is Associated with Prolonged Survival and Reduced Inflammation in ESRD Patients

Overview

Journal Am J Nephrol

Publisher Karger

Specialty Nephrology

Date 2008 Jul 1

PMID 18587236

Citations 16

Authors

Giuseppe Cianciolo

Gaetano La Manna

Luigi Coli

Gabriele Donati

Francesca DAddio

Elisa Persici

Giorgia Comai

Marylou Wratten

Ada Dormi

Vilma Mantovani

Gabriele Grossi

Sergio Stefoni

Affiliations

Soon will be listed here.

Abstract

Background: Hemodialysis (HD) patients have a greatly increased risk of cardiovascular morbidity and mortality. For this reason, attempts are often made to normalize hyperhomocysteinemia. This randomized prospective study sought to determine which risk factors are predictors of mortality and whether high doses of folates or 5-methyltetrahydrofolate (5-MTHF) could improve hyperhomocysteinemia and survival in HD patients.

Methods: 341 patients were divided into two groups: group A was treated with 50 mg i.v. 5-MTHF, and group B was treated with 5 mg/day oral folic acid. Both groups received i.v. vitamin B(6) and B(12). By dividing patients into C-reactive protein (CRP) quartiles, group A had the highest survival for CRP <12 mg/l, whereas no survival difference was found for group B. CRP was the only predictive risk factor for death (RR 1.17, range 1.04-1.30, p = 0.02). Dialysis age, hyperhomocysteinemia, methylenetetrahydrofolate reductase polymorphism, albumin, lipoprotein (a) and folate did not influence mortality risk. Survival in group A was higher than that in group B, namely 36.2 +/- 20.9 vs. 26.1 +/- 22.2 months (p = 0.003).

Results: Our results suggest that CRP, but not hyperhomocysteinemia, is the main risk factor for mortality in HD patients receiving vitamin supplements. Intravenous 5-MTHF seems to improve survival in HD patients independent from homocysteine lowering.

Citing Articles

The association of metabolic profile of folate with diabetic kidney disease: evidence from 2011-2020 cycles of the NHANES.

Liang Y, Ding L, Tao M, Zhu Y Ren Fail. 2024; 46(2):2420830.

PMID: 39477815 PMC: 11533242. DOI: 10.1080/0886022X.2024.2420830.

Does Vitamin Supplementation Play a Role in Chronic Kidney Disease?.

Juszczak A, Kupczak M, Konecki T Nutrients. 2023; 15(13).

PMID: 37447174 PMC: 10343669. DOI: 10.3390/nu15132847.

Homocysteine-Lowering Interventions in Chronic Kidney Disease.

Badri S, Vahdat S, Seirafian S, Pourfarzam M, Gholipur-Shahraki T, Ataei S J Res Pharm Pract. 2022; 10(3):114-124.

PMID: 35198504 PMC: 8809459. DOI: 10.4103/jrpp.jrpp_75_21.

Novel genes associated with folic acid-mediated metabolism in mouse: A bioinformatics study.

Zhao J, Zou W, Hu T PLoS One. 2020; 15(9):e0238940.

PMID: 32915913 PMC: 7485790. DOI: 10.1371/journal.pone.0238940.

Vitamin B Supplementation and Nutritional Intake of Methyl Donors in Patients with Chronic Kidney Disease: A Critical Review of the Impact on Epigenetic Machinery.

Cappuccilli M, Bergamini C, Giacomelli F, Cianciolo G, Donati G, Conte D Nutrients. 2020; 12(5).

PMID: 32349312 PMC: 7281987. DOI: 10.3390/nu12051234.

References

Nair A, Nemirovsky D, Kim M, Geer E, Farkouh M, Winston J . Elevated homocysteine levels in patients with end-stage renal disease. Mt Sinai J Med. 2005; 72(6):365-73. View

Stroes E, van Faassen E, Yo M, Martasek P, Boer P, Govers R . Folic acid reverts dysfunction of endothelial nitric oxide synthase. Circ Res. 2000; 86(11):1129-34. DOI: 10.1161/01.res.86.11.1129. View

Cheung A, Sarnak M, Yan G, Berkoben M, Heyka R, Kaufman A . Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study. Kidney Int. 2004; 65(6):2380-9. DOI: 10.1111/j.1523-1755.2004.00657.x. View

Chuang F, Fang J, Chen J, Lin C, Chen H, Lee C . Hyperhomocystinemia and the prevalence of symptomatic atherosclerotic vascular disease in Taiwanese chronic hemodialysis patients: a retrospective study. Ren Fail. 2003; 25(5):765-74. DOI: 10.1081/jdi-120024292. View

Toole J, Malinow M, Chambless L, Spence J, Pettigrew L, Howard V . Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial. JAMA. 2004; 291(5):565-75. DOI: 10.1001/jama.291.5.565. View

Ma J, Stampfer M, Hennekens C, Frosst P, Selhub J, Horsford J . Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation. 1996; 94(10):2410-6. DOI: 10.1161/01.cir.94.10.2410. View

van Guldener C, Janssen M, Lambert J, Ter Wee P, Jakobs C, Donker A . No change in impaired endothelial function after long-term folic acid therapy of hyperhomocysteinaemia in haemodialysis patients. Nephrol Dial Transplant. 1998; 13(1):106-12. DOI: 10.1093/ndt/13.1.106. View

Dennis V, Robinson K . Homocysteinemia and vascular disease in end-stage renal disease. Kidney Int Suppl. 1996; 57:S11-7. View

Sunder-Plassmann G, Fodinger M, Buchmayer H, Papagiannopoulos M, Wojcik J, Kletzmayr J . Effect of high dose folic acid therapy on hyperhomocysteinemia in hemodialysis patients: results of the Vienna multicenter study. J Am Soc Nephrol. 2000; 11(6):1106-1116. DOI: 10.1681/ASN.V1161106. View

10.

Araki A, Sako Y . Determination of free and total homocysteine in human plasma by high-performance liquid chromatography with fluorescence detection. J Chromatogr. 1987; 422:43-52. DOI: 10.1016/0378-4347(87)80438-3. View

11.

Skibola C, Smith M, Kane E, Roman E, Rollinson S, Cartwright R . Polymorphisms in the methylenetetrahydrofolate reductase gene are associated with susceptibility to acute leukemia in adults. Proc Natl Acad Sci U S A. 1999; 96(22):12810-5. PMC: 23109. DOI: 10.1073/pnas.96.22.12810. View

12.

Suliman M, Stenvinkel P, Heimburger O, Barany P, Lindholm B, Bergstrom J . Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy. Am J Kidney Dis. 2002; 40(3):480-8. DOI: 10.1053/ajkd.2002.34887. View

13.

Bowden R, Wyatt F, Wilson R, Wilborn C, Gentile M . Homocysteine and vascular access thrombosis in a cohort of end-stage renal disease patients. Ren Fail. 2004; 26(6):709-14. DOI: 10.1081/jdi-200037117. View

14.

Bayes B, Pastor M, Bonal J, Romero R . "New" cardiovascular risk factors in patients with chronic kidney disease: role of folic acid treatment. Kidney Int Suppl. 2004; (93):S39-43. DOI: 10.1111/j.1523-1755.2005.09309.x. View

15.

Touam M, Zingraff J, Jungers P, Chadefaux-Vekemans B, Drueke T, Massy Z . Effective correction of hyperhomocysteinemia in hemodialysis patients by intravenous folinic acid and pyridoxine therapy. Kidney Int. 1999; 56(6):2292-6. DOI: 10.1046/j.1523-1755.1999.00792.x. View

16.

Lonn E, Yusuf S, Arnold M, Sheridan P, Pogue J, Micks M . Homocysteine lowering with folic acid and B vitamins in vascular disease. N Engl J Med. 2006; 354(15):1567-77. DOI: 10.1056/NEJMoa060900. View

17.

Bonaa K, Njolstad I, Ueland P, Schirmer H, Tverdal A, Steigen T . Homocysteine lowering and cardiovascular events after acute myocardial infarction. N Engl J Med. 2006; 354(15):1578-88. DOI: 10.1056/NEJMoa055227. View

18.

Perna A, De Santo N, Ingrosso D . Adverse effects of hyperhomocysteinemia and their management by folic acid. Miner Electrolyte Metab. 1997; 23(3-6):174-8. View

19.

Nygard O, Vollset S, Refsum H, Stensvold I, Tverdal A, Nordrehaug J . Total plasma homocysteine and cardiovascular risk profile. The Hordaland Homocysteine Study. JAMA. 1995; 274(19):1526-33. DOI: 10.1001/jama.1995.03530190040032. View

20.

Mallamaci F, Bonanno G, Seminara G, Rapisarda F, Fatuzzo P, Candela V . Hyperhomocysteinemia and arteriovenous fistula thrombosis in hemodialysis patients. Am J Kidney Dis. 2005; 45(4):702-7. DOI: 10.1053/j.ajkd.2005.01.004. View